This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

OXFORD, United Kingdom, Jan. 09, 2025 (GLOBE NEWSWIRE) -- (MitoRx), a platform biotechnology company developing novel ...

The stock's fall snapped a two-day winning streak.

The UK's self-regulated system for disclosing payments from drug companies to health care professionals and organizations is ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

An initiative to improve care and standardize identification, assessment, referrals, and treatment for patients with HCM has been launched by the AHA.